Polyfunctional CD4+ T Cells As Targets for Tuberculosis Vaccination
- PMID: 29051764
- PMCID: PMC5633696
- DOI: 10.3389/fimmu.2017.01262
Polyfunctional CD4+ T Cells As Targets for Tuberculosis Vaccination
Abstract
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a leading cause of morbidity and mortality worldwide, despite the widespread use of the only licensed vaccine, Bacille Calmette Guerin (BCG). Eradication of TB will require a more effective vaccine, yet evaluation of new vaccine candidates is hampered by lack of defined correlates of protection. Animal and human studies of intracellular pathogens have extensively evaluated polyfunctional CD4+ T cells producing multiple pro-inflammatory cytokines (IFN-γ, TNF-α, and IL-2) as a possible correlate of protection from infection and disease. In this study, we review the published literature that evaluates whether or not BCG and/or novel TB vaccine candidates induce polyfunctional CD4+ T cells and if these T cell responses correlate with vaccine-mediated protection. Ample evidence suggests that BCG and several novel vaccine candidates evaluated in animal models and humans induce polyfunctional CD4+ T cells. However, while a number of studies utilizing the mouse TB model support that polyfunctional CD4+ T cells are associated with vaccine-induced protection, other studies in mouse and human infants demonstrate no correlation between these T cell responses and protection. We conclude that induction of polyfunctional CD4+ T cells is certainly not sufficient and may not even be necessary to mediate protection and suggest that other functional attributes, such as additional effector functions, T cell differentiation state, tissue homing potential, or long-term survival capacity of the T cell may be equally or more important to promote protection. Thus, a correlate of protection for TB vaccine development remains elusive. Future studies should address polyfunctional CD4+ T cells within the context of more comprehensive immunological signatures of protection that include other functions and phenotypes of T cells as well as the full spectrum of immune cells and mediators that participate in the immune response against Mtb.
Keywords: BCG; CD4+ T cells; T-cell immunity; polyfunctional T cells; protective immunity; tuberculosis; vaccine; vaccine-induced immunity.
References
-
- World Health Organization. Global Tuberculosis Report 2016. Geneva, Switzerland: World Health Organization; (2016).
-
- World Health Organization. The End TB Strategy: Global Strategy and Targets for Tuberculosis Prevention, Care and Control after 2015. Geneva, Switzerland: World Health Organization; (2015).
-
- Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet (2013) 381(9871):1021–8.10.1016/S0140-6736(13)60177-4 - DOI - PMC - PubMed
-
- Food and Drug Administration. Guidance for Industry: For the Evaluation of Combination Vaccines for Preventable Diseases: Production, Testing and Clinical Studies. Silver Springs: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; (1997).
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials